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Key questions
What is already known about this subject?
 ► Programmed cell death protein-1 (PD-1) inhibitors 
are at the centre of clinical practice for number of 
malignancies yet most patient fail to respond, thus, 
identifying biomarkers for patient selection is of 
essence.
 ► Although the negative impact of systemic inflam-
mation on prognosis of cancer patients is widely 
studied, the predictive meaning of systemic inflam-
matory status in patients receiving immune check-
point inhibitors (ICIs) is inadequately defined.
 ► Blood-based markers of systemic inflammation are 
shown to predict treatment benefit on cancer pa-
tients treated with ICIs but the knowledge about the 
independent prognostic role of C reactive protein 
(CRP) is scarce.
What does this study add?
 ► The current study investigated markers for systemic 
inflammation as a poor prognostic marker in cancer 
patients treated with PD-1 inhibitors using indepen-
dent, real-world cohorts.
 ► Results imply that elevated pretherapy CRP is strong 
indicator for adverse prognosis in multiple tumour 
types.
How might this impact on clinical practice?
 ► CRP value could prove to be a cheap and non-inva-
sive predictive marker and it should be investigated 
in prospective clinical trials.
AbstrAct
Background Anti-PD-(L)1 agents are standard of care 
treatments in various cancers but predictive factors for 
therapy selection are limited. We hypothesised that markers 
of systemic inflammation would predict adverse outcomes in 
multiple cancers treated with anti-PD-(L)1 agents.
Material and methods Discovery cohort consisted of 
patients who were treated with anti-programmed cell 
death protein-1 (PD-1) agents for advanced melanoma 
(MEL), non-small cell lung cancer (NSCLC) or renal and 
bladder cancers (GU) at Oulu University Hospital and 
had pretreatment C reactive protein (CRP), or neutrophil/
lymphocyte values available. As a validation cohort, we 
collected patients treated with anti-PD-1 agents from three 
other hospitals in Finland.
Results In the discovery cohort (n=56, MEL n=23, GU 
n=17, NSCLC n=16), elevated CRP over the upper limit of 
normal (ULN) (>10 mg/mL) indicated poor progression-free 
(PFS; p=0.005) and overall survival (OS; p=0.000004) 
in the whole population and in MEL subgroup. Elevated 
neutrophil-to-lymphocyte ratio (>2.65) also indicated 
inferior PFS (p=0.02) and OS (p=0.009). In the validation 
cohort (n=107, MEL n=44, NSCLC n=42, GU n=17, other 
n=4), CRP over ULN also was a strong indicator for poor 
PFS (p=0.0000008), and OS (p=0.000006) in the whole 
population, and in MEL and NSCLC also.
Conclusions Systemic inflammation suggested by 
elevated CRP is a very strong indicator for adverse 
prognosis on patients treated with anti-PD-(L)1 agents and 
has a potential negative predictive value for treatment with 
anti-PD-(L)1 agents. Prospective trials should investigate 
whether patients with elevated CRP gain any significant 
benefit from anti-PD-1 therapy.
IntRoduCtIon
Progress in the ﬁeld of immuno-oncology has 
changed the treatment landscape of multiple 
cancer types. Immune checkpoint inhibitor 
(ICI) therapies such as anti-PD-(L)1 and 
CTLA-4 antibodies, are now at the centre of 
clinical practice for a number of malignan-
cies and even durable responses are seen in 
advanced disease.1–10 In the programmed 
death ligand-1 (PD-L1)/programmed cell 
death protein-1 (PD-1) pathway, binding 
of PD-L1 on tumour cells and antigen 
presenting cells to the PD-1 receptor on T 
cells halts or limits T cell response by down-
regulating T cell proliferation, effector func-
tion and cytokine production.11 Typically, 
with PD-(L)1 inhibitors, responses are seen 
in 20%–40% of the patients yet most fail to 
respond. Therefore, predictive biomarkers 
are needed to guide the patient selection.
Despite the pervasive research on biomarker 
field, only a few biomarkers have proven to 
be clinically relevant such as tumour PD-L1 
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Figure 1 Flowchart demonstrating study selection for the discovery cohort. CRP, C reactive protein; GU, renal and bladder 
cancers; NSCLC, non-small cell lung cancer; OS, overall survival; PD-1, programmed cell death protein-1; PFS, progression-
free.
expression,12 13 tumour mutation burden (TMB),14 15 and 
in rare cases microsatellite instability, and mismatch-re-
pair deﬁciency.16 However, positive and negative predictive 
values of PD-L1 and TMB are low, and they are valid for 
patient selection only in particular cancers such as non-small 
cell lung cancer (NSCLC) and urothelial cancers. Never-
theless, these biomarkers are assessed from tumour biop-
sies, which are time consuming and not readily available. 
Blood-based biomarker assays as non-invasive analysis, are 
thus more compelling in various cancers.
The inflammation process has been proposed as a 
mechanism of immunoresistance in patients with cancer, 
promoting cancer growth17 and cancer-related inflam-
mation has been reported to be a marker of poor prog-
nosis.18 19 C reactive protein (CRP), a marker of systemic 
inflammation, has been used to make prognostic and 
predictive determinations of clinical outcome in cancer 
patients treated with ICIs.20–22 Other widely acknowl-
edged markers for systemic inflammation with prognostic 
value include neutrophil-to-lymphocyte ratio (NLR) and 
lactate-dehydrogenase (LDH). NLR is a marker for the 
general immune response to various stress stimuli, and 
it is shown to predict outcome among NSCLC and mela-
noma (MEL) patients treated with ICI therapies.23–26 
LDH level is a classic inflammatory marker in patients 
with cancer. High baseline levels of LDH are linked to 
poor survival and to inferior response to ICIs on MEL and 
NSCLC patients.27 28
The current retrospective study evaluates the correla-
tion of pretreatment CRP-values and NLR ratio to survival 
outcomes among cancer patients receiving anti-PD-1 
agents. We hypothesised that elevated CRP levels and 
high NLR ratio would predict poor outcome in multiple 
tumour types.
MateRIal and MetHods
Patients
All patients who had received at least one dose of intra-
venous anti-PD-(L)1 agent at Oulu University Hospital 
(Finland) 8/2014–9/2018 were retrospectively identified 
from the pharmacy records (Discovery cohort). Clinical 
variables included age, cancer type, TNM staging, Eastern 
Cooperative Oncology Group (ECOG) and blood sample 
results were manually collected from the electronic patient 
record. Laboratory values 4 weeks prior and 2 weeks post 
from the first anti-PD-(L)1 infusion were included, thus, 
all patients included in the analysis had received only 
one cycle of anti-PD-(L)1 therapy. If multiple laboratory 
values existed, the closest value to the first anti-PD-(L)1 
infusion was selected. Furthermore, if blood samples 
were taken during clinically confirmed acute infection, 
another preinfection or postinfection value was chosen 
which timely lined the closest to the first anti-PD-(L)1 
infusion. All the laboratories used the Finnish Accredi-
tation Service (FINAS) (SFS-EN ISO 15189) immuno-
turbidometric test for CRP. Progression-free (PFS) and 
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Table 1 Patientdemographics
n (%)
Age (median) 66
Gender
  Male 41 (73.2)
  Female 15 (26.8)
Tumour type
  Melanoma 23 (41.0)
  GU cancers 17 (30.4)
  NSCLC 16 (28.6)
Stage at diagnosis
  Stage IV 54 (96.4)
  Stage III 2 (3.6)
ECOG
  0 50 (89.3)
  1 6 (10.7)
Therapy line for metastatic 
cancer
  Line therapy 19 (33.9)
  Or later line 37 (66.1)
GU, renal and bladder cancers; NSCLC, non-small cell lung 
cancer.
Figure 2 Kaplan-Meier analysis for progression-free 
survival according to CRP in (A) whole study population, 
(B) melanoma patients, (C) GU cancer patients and (D) 
NSCLC patients of the discovery cohort. Crosses indicate 
censored events. CRP, C reactive protein; GU, renal and 
bladder cancers; NSCLC, non-small cell lung cancer; PFS, 
progression-free.
overall survival (OS) were calculated from the date of 
the first anti-PD-(L)1 infusion to documented tumour 
progression, death or end of follow-up (PFS) or to death 
or end of follow-up (OS). Tumour progression and/or 
death were counted as an event.
A validation cohort constituted of cancer patients 
treated with anti-PD-(L)1 therapy in three Finnish Univer-
sity Hospitals: Tampere, Helsinki and Kuopio. Patients, 
who had received at least one dose of anti-PD-(L)1 treat-
ment during 3/2015–9/2018 and had CRP values avail-
able as for discovery cohort, were included.
Data collection was carried out according to national 
legislation and under permit from the medical 
director of each University Hospital (Oulu Univer-
sity Hospital study no. 299/2016), Helsinki University 
Hospital (HUS/395/2018), Kuopio University Hospital 
(112/2018, 192/2018) and Tampere University Hospital 
(R18612). Anonymisation was performed before data 
analysis. Individual informed consents were not sought 
due to the register nature of the study.
statistical analysis
IBM SPSS Statistics V.24.0.0.0 for Windows was applied 
for statistical analysis. Survival was analysed by using the 
Kaplan-Meier method with the log-rank test. Receiver 
operating characteristic (ROC) curves were calculated 
for CRP and NLR to define the optimal cut-off-point. 
Multivariate analysis was performed using Cox regression 
analysis. Probability values below 0.05 were considered 
significant.
Results
discovery cohort
A total of 71 patients treated with single agent anti-PD-1 
therapy for advanced cancers in 2014–2018 at Oulu 
University Hospital Oncology Department were assessed 
for eligibility, and 56 of them were included in the final 
analysis (figure 1). Median age of the patients was 66.0 
years and majority of the patients were male (73.2%). 
The cohort included patients with MEL (n=23, 41.1%), 
renal and bladder cancers (GU) (n=17, 30.4%), and 
NSCLC (n=16, 28.6%). Detailed patient demographics 
are presented in table 1.
survival according to CRP in the discovery cohort
A ROC curve was calculated to define the optimal cut-off 
point of CRP in the cohort, and value 9.50 mg/mL was 
selected (online supplementary figure S1). We further 
rounded the value up to 10.0 which is a validated ULN 
rank for CRP. Median PFS for the whole cohort was 4.0 
months (CI 2.4 to 5.6) and there was statistical difference 
(p=0.005) between patients with CRP ≤10 (7.0 months, 
CI 2.9 to 11.1) and CRP >10 (2.0 months, CI 1.6 to 2.4) 
(figure 2A). Median OS for the whole cohort was 17.0 
months and there was statistical difference (p=0.000004) 
between patients with CRP ≤10 (not reached) and 
CRP >10 (10.0 months, CI 6.8 to 13.2) (figure 3A). In 
subgroup analysis for different cancer types (MEL, GU 
and NSCLC), there was statistically significant difference 
in PFS (p=0.03) and OS (p=0.0001) according to CRP in 
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Figure 3 Kaplan-Meier analysis for overall survival 
according to CRP in (A) whole study population, (B) 
melanoma patients, (C) GU cancer patients and (D) NSCLC 
patients of the discovery cohort. Crosses indicate censored 
events. CRP, C reactive protein; GU, renal and bladder 
cancers; NSCLC, non-small cell lung cancer; OS, overall 
survival.
Table 2 Other blood-based markers of systemic 
inflammation and their correlation to survival
Laboratory value P value
NLR, cut-off point >5
n=31
  PFS 0.21
  OS 0.056
Total leucocytes
n=58
  PFS 0.57
  OS 0.37
Total lymphocytes
n=31
  PFS 0.59
  OS 0.37
LDH
n=59
  PFS 0.54
  OS 0.32
LDH, lactate-dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; 
OS, overall survival; PFS, progression-free.
MEL but not GU or NSCLC. However, similar tendency 
for improved survival was seen also in NSCLC and GU 
cancers (figures 2B–D and 3B–D).
survival according to nlR in the discovery cohort
NLR was calculated by dividing the number of neutrophils 
by number of lymphocytes. ROC curve was calculated to 
define the optimal cut-off-point of the NLR ratio in our 
cohort, and the value 2.65 was chosen (online supplemen-
tary figure S2). Median PFS for the whole cohort was 4.0 
months (CI 1.8 to 6.3) and there was statistical difference 
(p=0.02) between patients with NLR ≤2.65 (7.0 months, 
CI 4.4 to 9.6) and NLR >2.65 (2.0 months, CI 1.5 to 2.5) 
(online supplementary figure S3A). Median OS for the 
whole cohort was 19.0 months (CI 9.3 to 28.7) and there 
was statistical difference (p=0.009) between patients with 
NLR ≤2.65 (19.0 months, CI 15.0 to 23.0) and NLR >2.65 
(7.0 months, CI 0.0 to 15.1) (online supplementary figure 
S3B). We also calculated PFS and OS with NLR ratio five 
defined as a cut-off-point in previous studies and the results 
showed statistically non-significant PFS and OS (table 2). 
Cox regression model was used to evaluate the dependence 
between CRP and NLR ratio. In multivariate analysis, these 
inflammatory biomarkers were non-independent.
survival according other studied blood-based markers in the 
discovery cohort
We also investigated additional blood-based markers 
suggestive of systemic inflammation and previously linked 
to poor survival and benefit from anti-PD-(L)1 agents. We 
investigated LDH, total leucocytes, total lymphocytes, 
and their correlation to PFS and OS. However, none of 
these markers predicted survival difference in the cohort 
(table 2).
survival according to CRP in validation cohort
A total of 107 cancer patients treated with single anti-
PD-1 therapy in three other Finnish University Hospitals 
between March 2015 and November 2018 were included 
in the cohort. Validation cohort consisted of patients with 
MEL (n=44, 41.1%), NSCLC (n=42, 39.3%), renal cell 
carcinoma (RCC) (n=13, 12.1%), bladder cancer (n=4, 
3.7%) and other not specified (n=4, 3.7%). Median PFS 
for the whole cohort was 7.0 months (CI 4.1 to 9.9) and 
there was statistical difference (p=0.0000008) between 
patients with CRP ≤10 (17.0 months, CI 10.2 to 23.8) and 
CRP >10 (3.0 months, CI 1.9 to 4.1) (figure 4A). Median 
OS for the whole cohort was 19.0 months and there was 
statistical difference (p=0.000006) between patients with 
CRP ≤10 (not reached) and CRP >10 (12.0 months, CI 
7.6 to 16.4) (figure 5A). In subgroup analysis for MEL, 
GU (RCC and bladder cancer) and NSCLCs, there was 
a statistically significant difference in PFS (p=0.00008) 
and OS (p=0.002) according to CRP in MEL and NSCLC 
PFS (p=0.03) and OS (p=0.006) but not in GU cancer. 
Though, similar tendency for improved survival was seen 
in GU cancer (figures 4B–D and 5B–D).
dIsCussIon
The negative impact of systemic inflammation on prog-
nosis of cancer patients receiving chemotherapy and 
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Figure 4 Kaplan-Meier analysis for progression-free 
survival according to CRP in (A) whole study population, 
(B) melanoma patients, (C) NSCLC patients and (D) GU 
cancer patients of the validation cohort. Crosses indicate 
censored events. CRP, C reactive protein; GU, renal and 
bladder cancers; NSCLC, non-small cell lung cancer; PFS, 
progression-free.
Figure 5 Kaplan-Meier analysis for overall survival 
according to CRP in (A) whole study population, (B) 
melanoma patients, (C) NSCLC patients and (D) GU cancer 
patients of the validation cohort. Crosses indicate censored 
events. CRP, C reactive protein; GU, renal and bladder 
cancers; NSCLC, non-small cell lung cancer; OS, overall 
survival.
targeted therapies is widely studied,29 30 but the role of 
systemic inflammatory status to help predict benefit 
of immunotherapy is inadequately characterised. The 
role of tumour microenvironment (TME), the area 
immediately surrounding the tumour which is typically 
composed of non-malignant lymphoid and/or myeloid 
cells as well as fibroblasts, vascular cells and lymphatic 
vessels, in predicting treatment response for ICIs is under 
fierce investigation. Analysis of genomic and transcrip-
tomic data has led to the discovery of so called metagene 
signatures and distinctive mutational landscapes with 
prognostic and predictive nature in cancer patients.31–34 
However, implementing a DNA or RNA-based gene signa-
ture is challenging from a clinical perspective, and more 
simplified surrogate biomarkers are needed.
Peripheral blood-based markers for systemic inflam-
mation such as NLR and LDH have been shown to have 
prognostic,24 35 36 and predictive20 impact on cancer 
patients receiving ICIs. CRP is an acute phase protein 
which reflects tissue injury, and its synthesis is influ-
enced by many factors including interleukin 1 (IL-1) and 
tumour necrosis factor (TNF).37 CRP is a known marker 
for systemic inflammation but its correlation to treatment 
benefit from anti-PD-(L)1 agents is scarcely studied,28 38–40 
and little is known about the independent prognostic 
role of CRP level.
The current study investigated the role of CRP and other 
markers for systemic inflammation in multiple advanced 
cancers treated with anti-PD-1 therapy. Interestingly, the 
optimal cut-off value for CRP as prognostic marker in 
anti-PD-1 treated patients was 10 mg/mL which is also the 
ULN value for CRP in most laboratories. In the discovery 
cohort, median PFS and OS were 4.0 and 17.0 months 
which were substantially lower in patients with elevated 
CRP (2.0 and 10.0 months, respectively). We also verified 
our results with validation cohort of patients treated with 
anti-PD-(L)1 agents in three other hospitals. Median PFS 
and OS (7.0 and 19.0 months) were similar in the valida-
tion cohort and there was statistical difference between 
survivals according to CRP. These results highlight 
the role of elevated CRP and systemic inflammation as 
markers for poor prognosis in patients treated with anti-
PD-(L)1 agents. NLR was also investigated but it proved 
inferior to CRP in the discovery cohort and was not 
further investigated in the validation cohort. Multivariate 
analysis, however, revealed that CRP and NLR were not 
independent prognostic markers suggesting that both 
reflect systemic inflammation with poor prognosis on 
anti-PD-(L)1 therapy treated patients.
The strengths of the current study include investigating 
the role of systemic inflammation using two independent, 
multicentre cohorts consisting of real-world patients 
treated with anti-PD-1 agents. Furthermore, our study 
investigated multiple different tumour types (MEL, GU 
cancers and NSCLC) which represent the most common 
cancers treated with anti-PD-(L)1 therapy. To our knowl-
edge, current study is the first investigating systemic 
inflammation markers in multiple tumour types using 
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independent cohorts. The results enable us to conclude 
generalisation of elevated CRP as a poor prognostic 
marker in cancer patients treated with anti-PD-1 therapy.
The current study has some limitations. Retrospective 
collection of patients and inclusion of only those who were 
treated with anti-PD-(L)1 agents could bias the results 
and generate prognostic but not true predictive informa-
tion of the studied markers. The relatively small sample 
size is another challenge. Possible confounding factors as 
concurrent use of medications that could have affected 
the blood biomarkers were not analysed. However, 
low PFS figures (median 2–3 months) on patients with 
elevated CRP levels are highly suggestive of low or no 
benefit of anti-PD-(L)1 therapy. Survival outcomes of our 
cohorts were significant in the whole population and in 
MEL (both cohorts) and NSCLC (validation cohort) but 
not in the others. In all, survival differences were similar 
in all the studied cancers even though not reaching statis-
tical significance which is most likely due to small number 
of patients in some of the cohorts.
Even though results of the current study are convincing, 
they are hypothesis generating. Prospective trials should 
investigate whether patients with elevated markers for 
systemic inflammation gain any significant benefit from 
single agent anti-PD-(L)1 therapy. We cannot conclude 
whether our results with systemic inflammation and 
poor prognosis on anti-PD-1 agents can be generalised 
to combination or adjuvant treatment with these agents. 
Future studies should aim to investigate whether systemic 
inflammation is marker of immunosuppression or func-
tional component in immunosuppression. If latter is 
true, this might open new therapeutic opportunities for 
better cancer care. According to preclinical studies, IL-1 
beta (IL-1β) is a master cytokine in tumour progression, 
and besides hindering the tumour growth, blocking 
IL-1β facilitates checkpoint inhibition by anti-PD-1s. In 
IL-1β-deficient mouse, low levels of the chemokine CCL2 
hamper monocyte recruitment, and together with low 
levels of colony-stimulating factor-1 (CSF-1) inhibit their 
differentiation to macrophages in TME. The low levels of 
macrophages in IL-1β-deficient mouse result in relatively 
high percentage of specific subtype of dendritic cells in 
the tumours, which secrete IL-12 fostering the antitumor 
immunity through activated CD8+ lymphocytes expressing 
interferon gamma (IFN-γ), tumour necrosis factor-alpha 
(TNF-α) and granzyme B, infiltrating tumours and 
inducing regression 41 . There are ongoing clinical studies 
investigating lowering CRP with medications such as IL-1β 
antibodies in combination to PD-1 agents ( ClinicalTrials. 
gov Identifier: NCT03631199).
In conclusion, the current study investigated markers 
for systemic inflammation as a poor prognostic marker in 
cancer patients treated with anti-PD-1 agents using inde-
pendent, real-world cohorts. The results suggest a strong 
negative prognostic role of elevated pretherapy CRP in 
anti-PD-1 therapy treated patients. CRP value could prove 
to be a cheap and non-invasive predictive marker and it 
should be investigated in prospective clinical trials.
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